Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cheadle

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Expert Opinion on Biological Therapy|April 18, 2015
Immuno-regulatory antibodies for the treatment of cancerJamie Honeychurch, Eleanor J Cheadle, Simon J Dovedi, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2009
The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, ItalyJohn S Bridgeman, David E Gilham, Robert E Hawkins, et al.
Nature|September 23, 2021
Three-dimensional magnetic stripes require slow cooling in fast-spread lower ocean crustSarah M Maher, Jeffrey S Gee, Michael J Cheadle, et al.
Immunological Reviews|December 17, 2013
CAR T cells: driving the road from the laboratory to the clinicEleanor J Cheadle, Hannah Gornall, Vania Baldan, et al.
British Journal of Haematology|April 22, 2005
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cellsEleanor J Cheadle, David E Gilham, Fiona C Thistlethwaite, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cellsEleanor J Cheadle, Robert E Hawkins, Hayley Batha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2010
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cellsEleanor J Cheadle, Robert E Hawkins, Hayley Batha, et al.
Leukemia|July 29, 2017
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Leukemia|November 29, 2016
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Gene Therapy|December 2, 2011
Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cellsE J Cheadle, D G Rothwell, J S Bridgeman, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Expert Opinion on Biological Therapy|April 18, 2015
Immuno-regulatory antibodies for the treatment of cancerJamie Honeychurch, Eleanor J Cheadle, Simon J Dovedi, et al.
Cancer Immunology, Immunotherapy : CII|August 12, 2009
The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, ItalyJohn S Bridgeman, David E Gilham, Robert E Hawkins, et al.
Nature|September 23, 2021
Three-dimensional magnetic stripes require slow cooling in fast-spread lower ocean crustSarah M Maher, Jeffrey S Gee, Michael J Cheadle, et al.
Immunological Reviews|December 17, 2013
CAR T cells: driving the road from the laboratory to the clinicEleanor J Cheadle, Hannah Gornall, Vania Baldan, et al.
British Journal of Haematology|April 22, 2005
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cellsEleanor J Cheadle, David E Gilham, Fiona C Thistlethwaite, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cellsEleanor J Cheadle, Robert E Hawkins, Hayley Batha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2010
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cellsEleanor J Cheadle, Robert E Hawkins, Hayley Batha, et al.
Leukemia|July 29, 2017
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Leukemia|November 29, 2016
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Gene Therapy|December 2, 2011
Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cellsE J Cheadle, D G Rothwell, J S Bridgeman, et al.
Pageof 8